Please upgrade your browser.
Kidney Cancer Association Applauds UK Drug Approval
Change of Tack Shows Policy Shift and Saves Lives
Evanston, IL, February 5, 2009 – The National Institute of Health and Clinical Excellence (NICE), the review body for the UK’s National Health Service, yesterday reversed an earlier decision and approved a drug for metastatic renal cell carcinoma. The decision marks an enormous victory for advanced-stage kidney cancer patients as well as the advocates who applied pressure on NICE to change their policy regarding lifesaving drugs for terminal patients.
|Powered by NeonCRM|